

**EISAI ENTERS COMMUNITY DEVELOPMENT PARTNERSHIP AGREEMENT WITH
CITY OF YOKOHAMA TO PROMOTE LOCAL DEMENTIA SUPPORT INITIATIVES**

[Notes to editors]

1. Eisai's Commitment to Dementia Initiatives

Since launching the Alzheimer's disease treatment Aricept[®], Eisai has been committed to enhancing the value that the drug provides patients through development of new formulations and additional indications, organizing disease education and awareness activities that seek to promote early diagnosis and treatment, and the improvement of diagnostic technologies. In Japan, Aricept reflects the diverse needs of patients and caregivers through the availability of a wide range of formulations, including tablets, orally disintegrating tablets, fine granules, an oral jelly, and a dry syrup formulation. Eisai is also currently conducting clinical development projects for Aricept in Japan, including to